Jason Slakter, MD
Enriched profileClinical Professor of Ophthalmology, NYU Grossman School of Medicine; Founder and Medical Director, Vitreous Retina Macula Consultants of New York (VRMNY) · NYU Grossman School of Medicine
Jason Slakter is Clinical Professor of Ophthalmology, NYU Grossman School of Medicine; Founder and Medical Director, Vitreous Retina Macula Consultants of New York (VRMNY) at NYU Grossman School of Medicine. ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 2 Sept 2026
Jason S. Slakter, MD, is Clinical Professor of Ophthalmology, NYU Grossman School of Medicine. The public record shows 192 publications with 16,592 citations (h-index 57), centered on Macular Degeneration (AMD). It also documents an investigator role on 7 registered clinical trials, industry payments reported by 9 companies.
- Top research focus: Macular Degeneration (AMD)
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
Sponsor: Vitreous -Retina- Macula Consultants of New York
- Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
Sponsor: Potentia Pharmaceuticals, Inc.
- Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
Sponsor: Vitreous -Retina- Macula Consultants of New York
Industry payments
Updated 2 Sept 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20251 payment
- ABBVIE INC.Program year20252 payments
- Apellis Pharmaceuticals, Inc.Program year20244 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
97.3%Antineovascularisation agents97.1%Faricimab-svoa100%Part B, office-administered≥48 patientsProstaglandin Analog0.1%Latanoprost100%Part D<11 patientsCancer & immunology
2.6%Vascular Endothelial Growth Factor Inhibitor2.6%Aflibercept100%Part B, office-administered≥53 patientsMusculoskeletal
0.1%Cyclooxygenase Inhibitor0.1%Ketorolac Tromethamine100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/jason-s-slakter-md-32260715
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/jason-slakter-005a64102
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/vrm.ny/p/Cs4WJ_Fxr7y
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
empoweredpatientradio.com/podcast/advances-in-treating-wet-age-related-macular-degeneration-with-dr-jason-slakter-ohr-pharmaceutical
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →empoweredpatientradio.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nyulangone.org ↗
- Fellowship in Vitreoretinal Surgery/Medical and Surgical Retinal Diseases
Manhattan Eye, Ear & Throat Hospital
1988provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nyulangone.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nyulangone.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nyulangone.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vrmny.com ↗
Editorial & leadership roles
journal and society appointments- Founding Editor-in-Chief
Retinal Physician journal
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vrmny.com ↗ - Member
American Ophthalmological Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vrmny.com ↗ - Member
Retina Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vrmny.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vrmny.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vrmny.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vrmny.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globenewswire.com ↗
- Former Assistant Clinical Professor of Ophthalmology
College of Physicians and Surgeons, Columbia University
2001provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ois.net ↗ - Founder and Director
Digital Angiography Reading Center (DARC), over 1,000 certified clinical sites in 44+ countries for retinal clinical trial imaging
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
- Podcast guest: Empowered Patient Podcast
"Advances in Treating Wet Age-Related Macular Degeneration with Dr. Jason Slakter"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →empoweredpatientradio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jill Buyon, MD
NYU Grossman School of Medicine
Jeffrey Berger, MD
NYU Grossman School of Medicine
Mark Mulligan, MD
NYU Grossman School of Medicine
David Goldfarb, MD
NYU Grossman School of Medicine